New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation

Authors

  • A. Tripodi,

    1. From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Cà Granda Maggiore Hospital Foundation and Università degli Studi di Milano, Milano, Italy
    Search for more papers by this author
  • G. Palareti

    1. Divsion of Angiology and Blood Coagulation, S.Orsola-Malpighi University Hospital, Bologna, Italy
    Search for more papers by this author

A. Tripodi, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Cà Granda Maggiore Hospital Foundation and Università degli Studi di Milano, Via Pace 9, 20122-Milano, Italy. (fax: +39 02 50320723; email: armando.tripodi@unimi.it)

Abstract

Abstract.  Tripodi A, Palareti G (IRCCS Cà Granda Maggiore Hospital Foundation and Università degli Studi di Milano, Milano, Italy; S.Orsola-Malpighi University Hospital, Bologna, Italy). New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation (Review). J Intern Med 2012; 271: 554–565.

Venous thromboembolism (including deep vein thrombosis and pulmonary embolism) and atrial fibrillation are common conditions in Western countries. The mainstay of treatment and prevention for these diseases is fast-acting anticoagulant drugs such as heparins and vitamin K antagonists. The use of these drugs is, however, complex and demanding for both patients and physicians. Recently, new antithrombotic drugs that act directly by inhibiting activated coagulation factors such as factor X or thrombin have been developed and investigated in phase III clinical trials. The aim of this article is to review: (i) the need to develop new drugs; (ii) their efficacy/safety as demonstrated in clinical trials; (iii) the need for laboratory monitoring and (iv) the direction towards the use of these new drugs in the real-life clinical situation.

Ancillary